Glenmede Trust Co. NA maintained its position in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,324 shares of the company’s stock at the end of the first quarter. Glenmede Trust Co. NA’s holdings in Syros Pharmaceuticals were worth $113,000 as of its most recent filing with the SEC.
Other institutional investors have also recently made changes to their positions in the company. Redmile Group LLC increased its position in shares of Syros Pharmaceuticals by 0.5% in the first quarter. Redmile Group LLC now owns 952,740 shares of the company’s stock worth $15,177,000 after buying an additional 4,300 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Syros Pharmaceuticals during the first quarter worth approximately $185,000. Finally, Wells Fargo & Company MN purchased a new position in shares of Syros Pharmaceuticals during the first quarter worth approximately $225,000. Institutional investors own 49.45% of the company’s stock.
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) opened at 19.32 on Friday. Syros Pharmaceuticals, Inc. has a one year low of $8.16 and a one year high of $19.66. The stock has a 50 day moving average of $16.96 and a 200-day moving average of $14.31. The stock’s market cap is $505.80 million.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Monday, May 15th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.10. The company had revenue of $1.10 million for the quarter. Analysts anticipate that Syros Pharmaceuticals, Inc. will post ($2.15) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Glenmede Trust Co. NA Has $113,000 Stake in Syros Pharmaceuticals, Inc. (SYRS)” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://stocknewstimes.com/2017/07/22/glenmede-trust-co-na-has-113000-stake-in-syros-pharmaceuticals-inc-syrs.html.
A number of equities analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday. ValuEngine upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Oppenheimer Holdings, Inc. set a $28.00 price target on shares of Syros Pharmaceuticals and gave the company a “buy” rating in a report on Monday, June 12th. Finally, Wedbush reiterated an “outperform” rating and issued a $22.00 price target on shares of Syros Pharmaceuticals in a report on Tuesday, May 16th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $20.86.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Want to see what other hedge funds are holding SYRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syros Pharmaceuticals, Inc. (NASDAQ:SYRS).
Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
